BlockBeats News, November 20th, the inaugural MSKE Asia-Pacific Leadership Summit successfully concluded in Bangkok, Thailand on November 20th. The conference revolved around the theme of "Global Vision × Regional Momentum × Innovative Practice," where policy representatives, blockchain community leaders, and technical experts from various countries shared the latest trends and insights.
Attendees widely believe that the Asia-Pacific region will become a crucial growth engine in the digital asset era. Jeremy, a representative of the global Bitcoin community, Noah, the Asia-Pacific community lead, and Vasily, the architect of the inscriptions system, emphasized the long-term value of inscription economics on-site and noted that MSKE has the foundation and potential to go global.
Blockchain financial expert Huang Yuchen stated: "RWA is the biggest gateway for blockchain to enter the mainstream, and MSKE's advantage lies in its real-world connectivity." This became one of the highlighted viewpoints at the event.
The summit also announced MSKE's future strategic direction, including global ecosystem expansion, technological iteration and upgrades, and the implementation of applications tailored for real-world scenarios. This event signifies MSKE's formal entry into a new stage of international development.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.